1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETipepidine hydrochlorideCat. No.: HY-121685ACAS No.: 1449686-84-3分式: CHClNS分量: 311.89作靶點: Dopamine Receptor作通路: GPCR/G Protein; Neuronal Signaling儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DM

2、SO : 41.67 mg/mL (133.60 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.2063 mL 16.0313 mL 32.0626 mL5 mM 0.6413 mL 3.2063 mL 6.4125 mL10 mM 0.3206 mL 1.6031 mL 3.2063 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內實驗 請根據您的實驗動物和給藥式選擇適當的溶解案，配制前請先配制澄的儲備液，再依次添加助溶劑(為保證實驗結果的可靠性

3、，體內實驗的作液，建議您現(xiàn)現(xiàn)配，當天使；澄的儲備液可以根據儲存條件，適當保存；以下溶劑前的百分指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (6.67 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (6.67 mM); Clear solution3. 請依序添加每種溶劑： 10% DMSO 90% corn oi

4、lSolubility: 2.08 mg/mL (6.67 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Tipepidine hydrochloride 可逆地抑制多巴胺 D2 受體介導的 GIRK 電流 (IDA(GIRK)，從激活 VTA 多巴胺神經元， IC50 為 7.0 M。Tipepidine hydrochloride種醉性鎮(zhèn)咳藥，具有抗抑郁樣作。IC50 & Target IC50: 7.0 M (dopamine D2 receptor)

5、1體內研究 Tipepidine (i.p.; 10-40 mg/kg; 0.5-23 hours) significantly decreases the immobility time in the forcedswimming test in ACTH-treated rats. Tipepidine (i.p.; 40 mg/kg) increases the extracellular dopamine level ofthe nucleus accumbens (NAc) in ACTH-treated rats 2.Animal Model: Male Wistar rats w

6、eighting 150-240 g (5-7 weeks old) 2Dosage: 10, 20 and 40 mg/kgAdministration: I.p.; 0.5, 5, 23 hoursResult: Decreased the immobility time in the forced swimming test in ACTH-treated rats.REFERENCES1. Hamasaki R, et al. Tipepidine activates VTA dopamine neuron via inhibiting dopamine D receptor-medi

7、ated inward rectifying K current.Neuroscience. 2013 Nov 12;252:24-34.2. Kawaura K, et al. Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect in the forced swimming test inadrenocorticotropic hormone-treated rats. Behav Brain Res. 2016 Apr 1;302:269-78.McePdfHeightCaution: Product has not been fully validated for medical applications.For research us